Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 8 for:    corvus

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04734873
Recruitment Status : Recruiting
First Posted : February 2, 2021
Last Update Posted : February 21, 2021
Sponsor:
Information provided by (Responsible Party):
Corvus Pharmaceuticals, Inc.

Brief Summary:
This is a phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately symptomatic hospitalized Covid-19 patients with the primary objective to compare the proportion of participants alive and respiratory failure free between CPI-006 plus SOC versus placebo plus SOC.

Condition or disease Intervention/treatment Phase
Covid-19 Drug: CPI-006 2 mg/kg + SOC Drug: CPI-006 1 mg/kg + SOC Drug: Placebo + SOC Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 3, Randomized, Placebo Controlled, Double-blind, Multicenter, Stratified Study of CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
Estimated Study Start Date : February 2021
Estimated Primary Completion Date : December 30, 2021
Estimated Study Completion Date : January 30, 2022

Arm Intervention/treatment
Experimental: CPI-006 (2 mg/kg) Plus Standard of Care
Participants will receive a single dose of CPI-006 at 2 mg/kg up to a maximum dose of 200 mg intravenously on Day 1 plus standard of care.
Drug: CPI-006 2 mg/kg + SOC
IV CPI-006 2 mg/kg up to a maximum dose of 200 mg plus standard of care

Experimental: CPI-006 (1 mg/kg) Plus Standard of Care
Participants will receive a single dose of CPI-006 at 1 mg/kg up to a maximum dose of 100 mg intravenously on Day 1 plus standard of care.
Drug: CPI-006 1 mg/kg + SOC
IV CPI-006 1 mg/kg up to a maximum dose of 100 mg plus standard of care

Placebo Comparator: Placebo Plus Standard of Care
Participants will receive a single dose of placebo intravenously on Day 1 plus standard of care.
Drug: Placebo + SOC
IV placebo plus standard of care




Primary Outcome Measures :
  1. To compare the proportion of participants alive and respiratory failure free of CPI-006 plus SOC versus placebo plus SOC [ Time Frame: During the 28 days after dosing ]
    Proportion of participants who are alive and free from respiratory deterioration using the 8-point ordinal scale


Secondary Outcome Measures :
  1. To compare the time to recovery of CPI-006 plus SOC versus placebo plus SOC [ Time Frame: During the 28 days after dosing ]
    Time to recovery after dosing measured by the 8-point ordinal scale

  2. To compare the time to clinical improvement of CPI-006 plus SOC versus placebo plus SOC [ Time Frame: Up to Day 28 ]
    Time to clinical improvement measured by the 8-point ordinal scale

  3. To compare the change from baseline in the level of antibodies targeting the receptor binding domain (RBD) of SARS-CoV-2 [ Time Frame: Baseline, Days 7, 14, 21 and 28 ]
    Measure the change from baseline level of IgG targeting the RBD



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmed positive by polymerase chain reaction (PCR) or antigen test for SARS-CoV-2 within 72 hours before randomization
  • Onset of symptoms not more than 7 days prior to randomization
  • Hospitalized for Covid-19 for ≤72 hours with mild to moderate Covid-19 symptoms
  • Maintains O2 saturation of ≥93% on room air or supplemental O2, including high-flow and non-invasive ventilation, at randomization
  • Adequate organ function
  • Participants of child-bearing age must agree to use adequate contraception for 6 weeks after study treatment administration

Exclusion Criteria:

  • Signs of acute respiratory distress syndrome or respiratory failure necessitating mechanical ventilation at time of screening/randomization or anticipated need for mechanical ventilation
  • History of severe chronic respiratory disease and requirement for long-term oxygen therapy
  • Uncontrolled active systemic infection or hemodynamic instability requiring admission to an intensive care unit
  • Malignant tumor receiving treatment, or other serious systemic diseases affecting life expectancy within 29 days of screening
  • Receipt of cancer chemotherapy or immunomodulatory drugs during preceding 2 months (steroids for treatment of Covid-19 are acceptable)
  • Current participation in other clinical trials including extended access programs
  • Active deep vein thrombosis or pulmonary embolism within last 6 months
  • Anticipated discharge from hospital or transfer to another hospital which is not a study site within 48 hours of admission
  • Active uncontrolled co-morbid disease that may interfere with study conduct or interpretation of findings
  • Known to be positive for HIV or positive test for chronic HBV infection or positive test for hepatitis C antibody
  • Convalescent plasma (CCP) or anti-SARS-CoV-2 monoclonal antibodies administered <24 hours prior to randomization. Must have recovered from any adverse events related to CCP treatment. Received chloroquine or hydroxychloroquine within last 7 days or during the study
  • Pregnancy or breast feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04734873


Contacts
Layout table for location contacts
Contact: Corvus Clinical Trials 650-900-4520 clinicaltrials@corvuspharma.com

Locations
Show Show 89 study locations
Sponsors and Collaborators
Corvus Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Study Chair: S. Mahabhashyam, MD, MPH Corvus Pharmaceuticals
Layout table for additonal information
Responsible Party: Corvus Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT04734873    
Other Study ID Numbers: CPI-006-003
First Posted: February 2, 2021    Key Record Dates
Last Update Posted: February 21, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Corvus Pharmaceuticals, Inc.:
SARS-CoV-2
Covid
Coronavirus
Covid19
COVID-19